Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by live attenuated measles vaccine in a heterologous prime-boost regimen.
Measles still causes considerable morbidity and mortality among infants and young children in developing countries. To develop a new public health tool to reduce this burden, we designed two Sindbis virus replicon vaccines encoding measles virus (MV) hemagglutinin (H) and fusion (F) proteins (pMSIN-H and pMSINHFdU). Our goal is to administer the vaccines to young infants at 6 and 10 weeks of age to prime the immune system to safely and effectively respond to subsequent immunization at age approximately 14 weeks with the licensed attenuated measles vaccine. In preparation for a phase 1 clinical trial, studies of plasmid distribution, integration, and toxicology were performed in rabbits. Biodistribution was assessed after a single DNA immunization delivered intradermally by needle-free injection. Toxicity was assessed using a heterologous prime-boost regimen consisting of a repeat-dose DNA prime followed by a live-attenuated measles vaccine boost. The only vaccine-related adverse effects observed were minimal transient erythema, edema, and inflammation confined to the injection site. Plasmids were detected in the subcutis and muscle at the site of inoculation. A small proportion of animals exhibited plasmids in the regional lymph nodes. There was no evidence of plasmid integration into the host genome. Both Sindbis-based vaccine plasmids were immunogenic in rabbits; pMSIN-H elicited higher virus-neutralizing antibody levels. Both vaccines were shown to be well tolerated and suitable for clinical trials and they are currently being tested in phase 1 studies in young adults.
Center for Vaccine Development, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Karina
K
Ramirez
Eileen M
EM
Barry
Jeffrey
J
Ulmer
Richard
R
Stout
James
J
Szabo
Scott
S
Manetz
Myron M
MM
Levine
Marcela F
MF
Pasetti
D000818:Animals; D006388:Hemagglutinins / Q000235:genetics; D006801:Humans; D007223:Infant; D007271:Injections, Intradermal; D008458:Measles Vaccine / Q000008:administration & dosage* / Q000235:genetics / Q000493:pharmacokinetics*; D010957:Plasmids / Q000493:pharmacokinetics; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000235:genetics; D012093:Replicon; D012845:Sindbis Virus / Q000235:genetics*; D014018:Tissue Distribution; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000493:pharmacokinetics
D006388:Hemagglutinins; D008458:Measles Vaccine; D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA